NCT01767766 2021-08-23Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic MalignanciesTG Therapeutics, Inc.Phase 1 Completed90 enrolled
NCT02006485 2019-11-05Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell MalignanciesTG Therapeutics, Inc.Phase 1 Completed160 enrolled